Sellas Life Sciences Group Inc SLS shares are trading higher by 8.3% at $8.24 after the company reported first-quarter EPS results up from last year.
Sellas Life Sciences reported quarterly losses of 16 cents per share, which represents a marked improvement over losses of 66 cents per share from the same period last year.
Sellas Life Sciences is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S, Nelipepimut-S, GALE-301/-302 and NeuVax.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
